Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies,

Renee C Prins, M.D., Stephen Spurgeon, MD, Jeffrey W Tyner, PhD, Luke B Fletcher, Abdusebur Jemal, Jade A Bryant, BS, Russell T Burke, Bill H Chang, MD, PhD, Tibor Kovacsovics, MD, Brian J. Druker, Marc M Loriaux, MD, PhD

Blood (2011) 118 (21): 3512.

https://doi.org/10.1182/blood.V118.21.3512.3512

Published: 2011

Journal Articles

A Highly Selective AKT 1/2 Inhibitor Abrogates AKT Signaling and Is Cytotoxic to Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells

Luke B Fletcher, Stephen Spurgeon, MD, Jeffrey W Tyner, PhD, Brian J Druker, MD, Marc M Loriaux, MD, PhD

Blood (2010) 116 (21): 3594.

https://doi.org/10.1182/blood.V116.21.3594.3594

Published: 2010

Journal Articles

P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity In Primary CLL Cells and Is Synergistic with Fludarabine at Low Concentrations

Stephen Spurgeon, MD, Luke B Fletcher, Jeffrey W Tyner, PhD, Brian J Druker, MD, Anjali Pandey, PhD, Uma Sinha, PhD, Marc M Loriaux, MD, PhD

Blood (2010) 116 (21): 2839.

https://doi.org/10.1182/blood.V116.21.2839.2839

Published: 2010

Journal Articles

A Small-Molecule Inhibitor Screen Rapidly Identifies Therapeutic Targets and Individualized Therapeutic Strategies In Patients with Acute and Chronic Leukemias

Jeffrey W Tyner, PhD, Stephen Spurgeon, MD, Luke B Fletcher, Wayne Yang, Tibor Kovacsovics, MD, Brian J Druker, MD, Marc M Loriaux, MD, PhD

Blood (2010) 116 (21): 2754.

https://doi.org/10.1182/blood.V116.21.2754.2754

Published: 2010

Journal Articles

Evaluation of CPX-351 (cytarabine:daunorubicin) Liposome Injection Anti-Leukemic Activity Against Primary Patient Leukemia Cells

Jeffrey W Tyner, PhD, Paul Tardi, PhD, Lawrence Mayer, PhD, Luke B Fletcher, Stephen Spurgeon, MD, Tibor Kovacsovics, MD, Marc M Loriaux, MD, PhD

Blood (2010) 116 (21): 2886.

https://doi.org/10.1182/blood.V116.21.2886.2886

Published: 2010

NARROW

CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies,

A Highly Selective AKT 1/2 Inhibitor Abrogates AKT Signaling and Is Cytotoxic to Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells

P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity In Primary CLL Cells and Is Synergistic with Fludarabine at Low Concentrations

A Small-Molecule Inhibitor Screen Rapidly Identifies Therapeutic Targets and Individualized Therapeutic Strategies In Patients with Acute and Chronic Leukemias

Evaluation of CPX-351 (cytarabine:daunorubicin) Liposome Injection Anti-Leukemic Activity Against Primary Patient Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies,

A Highly Selective AKT 1/2 Inhibitor Abrogates AKT Signaling and Is Cytotoxic to Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells

P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity In Primary CLL Cells and Is Synergistic with Fludarabine at Low Concentrations

A Small-Molecule Inhibitor Screen Rapidly Identifies Therapeutic Targets and Individualized Therapeutic Strategies In Patients with Acute and Chronic Leukemias

Evaluation of CPX-351 (cytarabine:daunorubicin) Liposome Injection Anti-Leukemic Activity Against Primary Patient Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only